Invited Mini Review : Therapeutic aptamers: developmental potential as anticancer drugs

Aptamers, composed of single-stranded DNA or RNA oligonucleotides that interact with target molecules through a specific three-dimensional structure, are selected from pools of combinatorial oligonucleotide libraries. With their high specificity and affinity for target proteins, ease of synthesis an...

Full description

Saved in:
Bibliographic Details
Published inBMB reports Vol. 48; no. 4; pp. 234 - 237
Main Authors Ji Won Lee, Hyun Jung Kim, Kyun Heo
Format Journal Article
LanguageKorean
Published 생화학분자생물학회 30.04.2015
Subjects
Application
Aptamer
Cancer
Oligonucleotide
Therapeutics
Online AccessGet full text

Cover

More Information
Summary:Aptamers, composed of single-stranded DNA or RNA oligonucleotides that interact with target molecules through a specific three-dimensional structure, are selected from pools of combinatorial oligonucleotide libraries. With their high specificity and affinity for target proteins, ease of synthesis and modification, and low immunogenicity and toxicity, aptamers are considered to be attractive molecules for development as anticancer therapeutics. Two aptamers - one targeting nucleolin and a second targeting CXCL12 - are currently undergoing clinical trials for treating cancer patients, and many more are under study. In this mini-review, we present the current clinical status of aptamers and aptamer-based cancer therapeutics. We also discuss advantages, limitations, and prospects for aptamers as cancer therapeutics. [BMB Reports 2015; 48(4): 234-237]
Bibliography:Korean Society for Biochemistry and Molecular Biology
ISSN:1976-6696